Conyers Dill & Pearman provided Cayman law advice to Bloomage BioTechnology Corporation Limited (the “Company”) in connection with its HK$3 billion privatisation by Grand Full Development Limited by way of a scheme of arrangement and its subsequent delisting from the Stock Exchange of Hong Kong.
Bloomage BioTechnology Corporation Limited develops, manufactures, and sells bio-chemical products in China and throughout Asia, the Americas, Europe and internationally. It offers sodium hyaluronic acid (HA) raw materials and end products for use in pharmaceutical, cosmetic, and health care products. The Company’s HA materials include pharmaceutical grade sodium hyaluronate under the Hyatrue name; food grade sodium hyaluronate under the HAPLEX name; cosmetic grade sodium hyaluronate under the Freda name; and Oligo HA under the Mini HA name. Its end products comprise of modified sodium hyaluronic gel for injection under the BioHyalux and Dermallure names. It also trades in HA end products and raw materials, cosmetic products and medical devices. The Company was founded in 2003 and is based in Central, Hong Kong.
Partner Richard Hall of Conyers’ Hong Kong office as well as Partner Ben Hobden of Conyers’ Cayman Islands office advised on the matter working alongside Sidley Austin (Hong Kong).